Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab with Lenalidomide or Talquetamab in Newly Diagnosed Multiple Myeloma (IFM 2022-01)
NCT06353022Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Jun 2024
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab in multiple myeloma (MM) (2 cohorts), sponsored by CHU de Nantes. Primary endpoints: Rate of sustained minimal residual disease (MRD) negativity (NGS, 10^-5) at 38 months and Rate of conversion from positive MRD to negative MRD (NGS, 10^-5) at 38 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06353022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353022.